Systematic review investigating the reporting of comorbidities and medication in randomized controlled trials of people with dementia

Toby Smith, Ian Maidment, Jennifer Hebding, Tairo Madzima, Francine Cheater, Jane Cross, Fiona Poland, Jacqueline White, John Young, Chris Fox

Research output: Contribution to journalArticle

Abstract

Objectives: dementia is a debilitating condition characterised by global loss of cognitive and intellectual functioning, which reduces social and occupational performance. This population frequently presents with medical co-morbidities such as hypertension, cardiovascular disease and diabetes. The CONSORT statement outlines recommended guidance on reporting of participant characteristics in clinical trials. It is, however, unclear how much these are adhered to in trials assessing people with dementia. This paper assesses the reporting of medical co-morbidities and prescribed medications for people with dementia within randomised controlled trial (RCT) reports. Design: a systematic review of the published literature from the databases AMED, CINAHL, MEDLINE, EMBASE and the Cochrane Clinical Trial Registry from 1 January 1997 to 9 January 2014 was undertaken in order to identify RCTs detailing baseline medical co-morbidities and prescribed medications . Eligible studies were appraised using the Critical Appraisal Skills Programme (CASP) RCT appraisal tool, and descriptive statistical analyses were calculated to determine point prevalence. Results: nine trials, including 1474 people with dementia, were identified presenting medical co-morbidity data. These indicated neurological disorders ( prevalence 91%), vascular disorders (prevalence 91%), cardiac disorders ( prevalence 74%) and ischaemic cerebrovascular disease ( prevalence 53%) were most frequently seen. Conclusions: published RCTs poorly report medical co-morbidities and medications for people with dementia. Future trials should include the report of these items to allow interpretation of whether the results are generalisable to frailer older populations.

Original languageEnglish
Pages (from-to)868-872
Number of pages5
JournalAge and Ageing
Volume43
Issue number6
Early online date19 Jul 2014
DOIs
Publication statusPublished - 6 Nov 2014

Fingerprint

Dementia
Comorbidity
Randomized Controlled Trials
Morbidity
Clinical Trials
Cerebrovascular Disorders
Nervous System Diseases
MEDLINE
Population
Blood Vessels
Registries
Cardiovascular Diseases
Databases
Hypertension

Bibliographical note

This is a pre-copyedited, author-produced PDF of an article accepted for publication in Age and Ageing following peer review. The version of record Smith, T., Maidment, I., Hebding, J., Madzima, T., Cheater, F., Cross, J., ... Fox, C. (2014). Systematic review investigating the reporting of comorbidities and medication in randomized controlled trials of people with dementia. Age and ageing, 43(6), 868-872. is available online at: http://ageing.oxfordjournals.org/content/43/6/868

Supplementary data: available to subscribers in Age and Ageing online.

Keywords

  • co-morbidity
  • cognitive impairment
  • dementia
  • older people
  • systematic review

Cite this

Smith, Toby ; Maidment, Ian ; Hebding, Jennifer ; Madzima, Tairo ; Cheater, Francine ; Cross, Jane ; Poland, Fiona ; White, Jacqueline ; Young, John ; Fox, Chris. / Systematic review investigating the reporting of comorbidities and medication in randomized controlled trials of people with dementia. In: Age and Ageing. 2014 ; Vol. 43, No. 6. pp. 868-872.
@article{0c5122df1fbe421f9f5c8630d3cb2b2c,
title = "Systematic review investigating the reporting of comorbidities and medication in randomized controlled trials of people with dementia",
abstract = "Objectives: dementia is a debilitating condition characterised by global loss of cognitive and intellectual functioning, which reduces social and occupational performance. This population frequently presents with medical co-morbidities such as hypertension, cardiovascular disease and diabetes. The CONSORT statement outlines recommended guidance on reporting of participant characteristics in clinical trials. It is, however, unclear how much these are adhered to in trials assessing people with dementia. This paper assesses the reporting of medical co-morbidities and prescribed medications for people with dementia within randomised controlled trial (RCT) reports. Design: a systematic review of the published literature from the databases AMED, CINAHL, MEDLINE, EMBASE and the Cochrane Clinical Trial Registry from 1 January 1997 to 9 January 2014 was undertaken in order to identify RCTs detailing baseline medical co-morbidities and prescribed medications . Eligible studies were appraised using the Critical Appraisal Skills Programme (CASP) RCT appraisal tool, and descriptive statistical analyses were calculated to determine point prevalence. Results: nine trials, including 1474 people with dementia, were identified presenting medical co-morbidity data. These indicated neurological disorders ( prevalence 91{\%}), vascular disorders (prevalence 91{\%}), cardiac disorders ( prevalence 74{\%}) and ischaemic cerebrovascular disease ( prevalence 53{\%}) were most frequently seen. Conclusions: published RCTs poorly report medical co-morbidities and medications for people with dementia. Future trials should include the report of these items to allow interpretation of whether the results are generalisable to frailer older populations.",
keywords = "co-morbidity, cognitive impairment, dementia, older people, systematic review",
author = "Toby Smith and Ian Maidment and Jennifer Hebding and Tairo Madzima and Francine Cheater and Jane Cross and Fiona Poland and Jacqueline White and John Young and Chris Fox",
note = "This is a pre-copyedited, author-produced PDF of an article accepted for publication in Age and Ageing following peer review. The version of record Smith, T., Maidment, I., Hebding, J., Madzima, T., Cheater, F., Cross, J., ... Fox, C. (2014). Systematic review investigating the reporting of comorbidities and medication in randomized controlled trials of people with dementia. Age and ageing, 43(6), 868-872. is available online at: http://ageing.oxfordjournals.org/content/43/6/868 Supplementary data: available to subscribers in Age and Ageing online.",
year = "2014",
month = "11",
day = "6",
doi = "10.1093/ageing/afu100",
language = "English",
volume = "43",
pages = "868--872",
journal = "Age and Ageing",
issn = "0002-0729",
publisher = "Oxford University Press",
number = "6",

}

Smith, T, Maidment, I, Hebding, J, Madzima, T, Cheater, F, Cross, J, Poland, F, White, J, Young, J & Fox, C 2014, 'Systematic review investigating the reporting of comorbidities and medication in randomized controlled trials of people with dementia', Age and Ageing, vol. 43, no. 6, pp. 868-872. https://doi.org/10.1093/ageing/afu100

Systematic review investigating the reporting of comorbidities and medication in randomized controlled trials of people with dementia. / Smith, Toby; Maidment, Ian; Hebding, Jennifer; Madzima, Tairo; Cheater, Francine; Cross, Jane; Poland, Fiona; White, Jacqueline; Young, John; Fox, Chris.

In: Age and Ageing, Vol. 43, No. 6, 06.11.2014, p. 868-872.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Systematic review investigating the reporting of comorbidities and medication in randomized controlled trials of people with dementia

AU - Smith, Toby

AU - Maidment, Ian

AU - Hebding, Jennifer

AU - Madzima, Tairo

AU - Cheater, Francine

AU - Cross, Jane

AU - Poland, Fiona

AU - White, Jacqueline

AU - Young, John

AU - Fox, Chris

N1 - This is a pre-copyedited, author-produced PDF of an article accepted for publication in Age and Ageing following peer review. The version of record Smith, T., Maidment, I., Hebding, J., Madzima, T., Cheater, F., Cross, J., ... Fox, C. (2014). Systematic review investigating the reporting of comorbidities and medication in randomized controlled trials of people with dementia. Age and ageing, 43(6), 868-872. is available online at: http://ageing.oxfordjournals.org/content/43/6/868 Supplementary data: available to subscribers in Age and Ageing online.

PY - 2014/11/6

Y1 - 2014/11/6

N2 - Objectives: dementia is a debilitating condition characterised by global loss of cognitive and intellectual functioning, which reduces social and occupational performance. This population frequently presents with medical co-morbidities such as hypertension, cardiovascular disease and diabetes. The CONSORT statement outlines recommended guidance on reporting of participant characteristics in clinical trials. It is, however, unclear how much these are adhered to in trials assessing people with dementia. This paper assesses the reporting of medical co-morbidities and prescribed medications for people with dementia within randomised controlled trial (RCT) reports. Design: a systematic review of the published literature from the databases AMED, CINAHL, MEDLINE, EMBASE and the Cochrane Clinical Trial Registry from 1 January 1997 to 9 January 2014 was undertaken in order to identify RCTs detailing baseline medical co-morbidities and prescribed medications . Eligible studies were appraised using the Critical Appraisal Skills Programme (CASP) RCT appraisal tool, and descriptive statistical analyses were calculated to determine point prevalence. Results: nine trials, including 1474 people with dementia, were identified presenting medical co-morbidity data. These indicated neurological disorders ( prevalence 91%), vascular disorders (prevalence 91%), cardiac disorders ( prevalence 74%) and ischaemic cerebrovascular disease ( prevalence 53%) were most frequently seen. Conclusions: published RCTs poorly report medical co-morbidities and medications for people with dementia. Future trials should include the report of these items to allow interpretation of whether the results are generalisable to frailer older populations.

AB - Objectives: dementia is a debilitating condition characterised by global loss of cognitive and intellectual functioning, which reduces social and occupational performance. This population frequently presents with medical co-morbidities such as hypertension, cardiovascular disease and diabetes. The CONSORT statement outlines recommended guidance on reporting of participant characteristics in clinical trials. It is, however, unclear how much these are adhered to in trials assessing people with dementia. This paper assesses the reporting of medical co-morbidities and prescribed medications for people with dementia within randomised controlled trial (RCT) reports. Design: a systematic review of the published literature from the databases AMED, CINAHL, MEDLINE, EMBASE and the Cochrane Clinical Trial Registry from 1 January 1997 to 9 January 2014 was undertaken in order to identify RCTs detailing baseline medical co-morbidities and prescribed medications . Eligible studies were appraised using the Critical Appraisal Skills Programme (CASP) RCT appraisal tool, and descriptive statistical analyses were calculated to determine point prevalence. Results: nine trials, including 1474 people with dementia, were identified presenting medical co-morbidity data. These indicated neurological disorders ( prevalence 91%), vascular disorders (prevalence 91%), cardiac disorders ( prevalence 74%) and ischaemic cerebrovascular disease ( prevalence 53%) were most frequently seen. Conclusions: published RCTs poorly report medical co-morbidities and medications for people with dementia. Future trials should include the report of these items to allow interpretation of whether the results are generalisable to frailer older populations.

KW - co-morbidity

KW - cognitive impairment

KW - dementia

KW - older people

KW - systematic review

UR - http://www.scopus.com/inward/record.url?scp=84911397619&partnerID=8YFLogxK

U2 - 10.1093/ageing/afu100

DO - 10.1093/ageing/afu100

M3 - Article

VL - 43

SP - 868

EP - 872

JO - Age and Ageing

JF - Age and Ageing

SN - 0002-0729

IS - 6

ER -